Corporate ActionMay 21, 2026, 06:32 AM
Immix Biopharma Prices $150M Underwritten Public Offering
AI Summary
Immix Biopharma, Inc. announced the pricing of an underwritten registered offering of 16,778,524 shares of its common stock at $8.94 per share. The offering is expected to generate gross proceeds of $150 million and is anticipated to close around May 22, 2026. Immix intends to use the net proceeds to fund NXC-201 development, working capital, and general corporate purposes, which is expected to meet the company's operational needs into mid-2028.
Key Highlights
- Immix Biopharma priced an underwritten registered offering of common stock.
- The offering includes 16,778,524 shares at a price of $8.94 per share.
- Gross proceeds are expected to be $150 million before deducting expenses.
- Net proceeds will fund NXC-201 development, working capital, and general corporate purposes.
- The offering is expected to extend the company's operational needs into mid-2028.
- Morgan Stanley is acting as the lead book-running manager for the offering.
Price Impact
More from IMMX